Since 2003, UroToday has been empowering both healthcare provider and patient with access to urological evidence-based diagnosis and treatment solutions from anywhere in the world.
Our philosophy is simple: provide free, accurate, timely, evidence-based urology news and information to both healthcare providers and patients, allowing them to stay ahead of relevant urologic conditions while better understanding symptoms and treatments.
UroToday® publishes a full spectrum of online medical articles about urology health and urologic diseases organized by conditions, treatments, and evidence-based guidelines to arm physicians, healthcare professionals, patients, caregivers and industry with the information and clinical decision-support tools needed to stay up-to-date in urology. Individual access is free for all users, with registration available for access to email newsletters and content notifications. UroToday is commercially supported by online advertising and sponsorships.
Channels include Urologic Cancer, Men's Health, Endourology & Urolithiasis, Pediatric Urology, and more, with topics ranging from Advanced Prostate Cancer to Vasectomy. Highly engaging video lectures of case studies (InSlides) are available for viewing, as are hundreds of abstracts, key opinion leader commentaries, important conference proceedings, and key events for planning your calendar.
Launched in 2015 as complement to UroToday, OncToday will set out to challenge traditional ways of engaging with oncology content online.
Through our exclusive virtual learning centers ("InterSections"), world-renowned physicians from leading oncology centers and institutes will discuss and provide commentary on the most relevant breakthroughs affecting cancer rate.
Like UroToday, evidence-based guidelines will be a key focus within all cancer areas and tumor types, including breast, gastrointestinal, genitourinary, gynecological, head and neck, hematologic, lung, skin, pediatric, and rare conditions. In addition, OncToday will provide focused learning exercises on key concepts affecting cancer care and diagnosis, including immunotherapy, molecular markers and targeted therapies.
OncToday is commercially supported by online advertising and sponsorships, allowing Digital Science Press to provide free individual access for all users, with registration available to provide content notifications via email newsletters.